Impact of Oral DFD-29, a Low-Dose Formulation of Minocycline, on Quality of Life in Patients with Rosacea: Results of Two Phase 3 Randomized Controlled Trials.
Year: 2025
Type: article
Abstract: OBJECTIVE: DFD-29 is a low-dose modified formulation of minocycline 40mg that has demonstrated efficacy and safety in patients with rosacea. We report the effect of DFD-29 on patient-reported assessments of disease severity and quality of life (QoL) from two clinical trials in patients with moderate-to-severe rosacea. METHODS: MVOR-1 (NCT05296629) and MVOR-2 (NCT05343455) were 16-week, randomized, double-blind, active- and placebo-controlled Phase III trials that compared the impact of oral DFD-29 (EMROSI, Journey Medical Corporation), doxycycline 40mg, and placebo in adults aged 18 years or older with moderate-to-severe rosacea. Changes in QoL were exploratory endpoints that were evaluated at baseline and Weeks 2, 4, 8, 12, and 16 using the Rosacea-Specific Quality of Life (RosaQoL) questionnaire and the Dermatology Life Quality Index (DLQI). RESULTS: <0.05) at Weeks 4, 8, and 12. LIMITATIONS: RosaQoL and DLQI were exploratory endpoints. CONCLUSION: These data suggest that DFD-29 may be useful in improving QoL in patients with moderate-to-severe rosacea.
Source: PubMed
Institutions: Henry Ford Health, Witten/Herdecke University, CentroDerm
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4417524204
FWCI:
Cites:
Cited by:
Related to: